Brief History

Dimerix was established in 2004 to commercialise a GPCR drug discovery platform based on the phenomenon of GPCR heteromerisation, or the ability of GPCRs to form higher-order complexes of GPCRs.

The laboratory of Professor Karin Eidne and Associate Professor Kevin Pfleger, located at the Western Australian Institute for Medical Research (WAIMR), developed novel methods of detecting the ability of GPCRs to form heteromer complexes and an ability to determine whether certain downstream intracellular signals were modified when ligands bind to a GPCR complex.

Dimerix received early investment capital from Starpharma Limited, an ASX-listed company, and from venture capital funds Foundation Capital, the Murdoch-Westscheme Enterprise Partnership and Stoneridge Ventures.